Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, Ignace
Smith, David C
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G
Weitzman, Ron
Buckanovich, Ronald J

September 2017

Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor recepto...

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

Pujade-Lauraine, Eric
Selle, Frédéric
Weber, Béatrice
Ray-Coquard, Isabelle-Laure
Vergote, Ignace
Sufliarsky, Jozef
Del Campo, Josep Maria
Lortholary, Alain
Lesoin, Anne
Follana, Philippe
Freyer, Gilles
Pardo, Beatriz
Vidal, Laura
Tholander, Bengt
Gladieff, Laurence
Sassi, Mouna
Garin-Chesa, Pilar
Nazabadioko, Serge
Marzin, Kristell
Pilz, Korinna
Joly, Florence

March 2016

Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apo...

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

최혜진

January 2015

BACKGROUND: We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GE...

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Despierre, Evelyn
Vergote, Ignace
Anderson, Ryan
Coens, Corneel
Katsaros, Dionyssios
Hirsch, Fred R
Boeckx, Bram
Varella-Garcia, Marileila
Ferrero, Annamaria
Ray-Coquard, Isabelle
Berns, Els M J J
Casado, Antonio
Lambrechts, Diether
Jimeno, Antonio
European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO), Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO), National Cancer Research Institute (NCRI), Australia New Zealand Gynaecological Oncology Group (ANZGOG), and the Mario Negri Gynecologic Oncology group (MaNGO)

December 2015

In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarke...

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Despierre, Evelyn
Vergote, Ignace
Anderson, Ryan
Coens, Corneel
Katsaros, Dionyssios
Hirsch, Fred R
Boeckx, Bram
Varella-Garcia, Marileila
Ferrero, Annamaria
Ray-Coquard, Isabelle
Berns, Els MJJ
Casado, Antonio
Lambrechts, Diether
Jimeno, Antonio
European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), and the Mario Negri Gynecologic Oncology group MaNGO

December 2015

In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarke...

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma

Hirte HW

April 2013

Hal W Hirte Department of Oncology, McMaster University, Hamilton, ON, Canada Abstract: The epiderma...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

OncoTargets and Therapy 2013:6 427–435 OncoTargets and Therapy Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma

Hal W Hirte
Correspondence Hal
W Hirte

August 2016

Abstract: The epidermal growth-factor receptor (EGFR) is overexpressed in the majority of epithelial...

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, Ignace
Smith, David C
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G
Weitzman, Ron
Buckanovich, Ronald J

September 2017

Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor recepto...

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, Ignace
Smith, David C
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G
Weitzman, Ron
Buckanovich, Ronald J

September 2017

Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor recepto...

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

Pujade-Lauraine, Eric
Selle, Frédéric
Weber, Béatrice
Ray-Coquard, Isabelle-Laure
Vergote, Ignace
Sufliarsky, Jozef
Del Campo, Josep Maria
Lortholary, Alain
Lesoin, Anne
Follana, Philippe
Freyer, Gilles
Pardo, Beatriz
Vidal, Laura
Tholander, Bengt
Gladieff, Laurence
Sassi, Mouna
Garin-Chesa, Pilar
Nazabadioko, Serge
Marzin, Kristell
Pilz, Korinna
Joly, Florence

March 2016

Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apo...

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

최혜진

January 2015

BACKGROUND: We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GE...

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Despierre, Evelyn
Vergote, Ignace
Anderson, Ryan
Coens, Corneel
Katsaros, Dionyssios
Hirsch, Fred R
Boeckx, Bram
Varella-Garcia, Marileila
Ferrero, Annamaria
Ray-Coquard, Isabelle
Berns, Els M J J
Casado, Antonio
Lambrechts, Diether
Jimeno, Antonio
European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO), Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO), National Cancer Research Institute (NCRI), Australia New Zealand Gynaecological Oncology Group (ANZGOG), and the Mario Negri Gynecologic Oncology group (MaNGO)

December 2015

In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarke...

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Despierre, Evelyn
Vergote, Ignace
Anderson, Ryan
Coens, Corneel
Katsaros, Dionyssios
Hirsch, Fred R
Boeckx, Bram
Varella-Garcia, Marileila
Ferrero, Annamaria
Ray-Coquard, Isabelle
Berns, Els MJJ
Casado, Antonio
Lambrechts, Diether
Jimeno, Antonio
European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), and the Mario Negri Gynecologic Oncology group MaNGO

December 2015

In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarke...

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma

Hirte HW

April 2013

Hal W Hirte Department of Oncology, McMaster University, Hamilton, ON, Canada Abstract: The epiderma...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

Erlotinib Added to Carboplatin and Paclitaxel as First-line Treatment of Ovarian Cancer: A Phase II Study Based on Surgical Reassessment

Runowicz, Carolyn D.

November 2010

Background The purpose of this study was to determine whether adding the anti-epidermal growth facto...

OncoTargets and Therapy 2013:6 427–435 OncoTargets and Therapy Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma

Hal W Hirte
Correspondence Hal
W Hirte

August 2016

Abstract: The epidermal growth-factor receptor (EGFR) is overexpressed in the majority of epithelial...

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, Ignace
Smith, David C
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G
Weitzman, Ron
Buckanovich, Ronald J

September 2017

Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor recepto...

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, Ignace
Smith, David C
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G
Weitzman, Ron
Buckanovich, Ronald J

September 2017

Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor recepto...

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

Pujade-Lauraine, Eric
Selle, Frédéric
Weber, Béatrice
Ray-Coquard, Isabelle-Laure
Vergote, Ignace
Sufliarsky, Jozef
Del Campo, Josep Maria
Lortholary, Alain
Lesoin, Anne
Follana, Philippe
Freyer, Gilles
Pardo, Beatriz
Vidal, Laura
Tholander, Bengt
Gladieff, Laurence
Sassi, Mouna
Garin-Chesa, Pilar
Nazabadioko, Serge
Marzin, Kristell
Pilz, Korinna
Joly, Florence

March 2016

Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apo...

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

최혜진

January 2015

BACKGROUND: We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GE...

Abstract

Extracted data

Abstract

Extracted data

Topics

Related items

Topics

Related items